Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
3,273 results
  • Bisphosphonates for osteoporosis in people with cystic fibrosis. [Review]
    Cochrane Database Syst Rev. 2023 01 10; 1:CD002010.Jeffery TC, Chang AB, Conwell LS
  • CONCLUSIONS: Oral and intravenous bisphosphonates may increase bone mineral density in people with cystic fibrosis, but there are insufficient data to determine whether treatment reduces fractures. Severe bone pain and flu-like symptoms may occur with intravenous bisphosphonates. Before any firm conclusions can be drawn, trials in larger populations, including children, and of longer duration are needed to determine effects on fracture rate and survival. Additional trials are needed to determine if bone pain is more common or severe (or both) with the more potent zoledronate and if corticosteroids can ameliorate or prevent these adverse events. Future trials should also assess gastrointestinal adverse effects associated with oral bisphosphonates.
  • Ocular Side Effects of Bisphosphonates: A Review of Literature. [Review]
    J Ocul Pharmacol Ther. 2023 Jan-Feb; 39(1):3-16.Chartrand NA, Lau CK, … Moshirfar M
  • In rare cases, bisphosphonates are well established to cause ocular inflammation, presenting as uveitis, episcleritis, scleritis, orbital inflammation, and/or conjunctivitis. Some reports of bisphosphonate-associated neuro-ophthalmic complications also exist. We identified 101 reports in the literature relating to bisphosphonate-associated ocular complications. In a great majority of cases, sympt…
  • Extensive Idiopathic Calcinosis in a Child - A Diagnostic and Therapeutic Imbroglio. [Case Reports]
    Indian Dermatol Online J. 2022 Nov-Dec; 13(6):775-777.Bhattarai D, Banday AZ, … Risal U
  • Idiopathic calcinosis is a disorder characterized by diffuse calcium deposits at various sites of the body. Etiopathogenic associations are described with inherited disorders, connective tissue disorders, infections, tumors, trauma, and endocrine disturbances. No diagnostic tests or standard therapeutic guidelines are established for this entity. There is paucity of literature on idiopathic calci…
  • Hyperthyroidism in McCune-Albright Syndrome - a case report. [Case Reports]
    J Pediatr Endocrinol Metab. 2022 Nov 10 [Online ahead of print]Rosinha P, Ramalho D, … Mirante A
  • CONCLUSIONS: This is a case of MAS-associated HT that reflects the deleterious effect of thyroid hormone excess on FD, reinforcing the need of having a low threshold for suspicion of HFE that may arise.
  • Updates on Paget's Disease of Bone. [Journal Article]
    Endocrinol Metab (Seoul). 2022 10; 37(5):732-743.Choi YJ, Sohn YB, Chung YS
  • Paget's disease of the bone is a prevalent bone disease characterized by disorganized bone remodeling; however, it is comparatively uncommon in East Asian countries, including China, Japan, and Korea. The exact cause still remains unknown. In genetically susceptible individuals, environmental triggers such as paramyxoviral infections are likely to cause the disease. Increased osteoclast activity …
  • Hypercalcemia: A Review. [Review]
    JAMA. 2022 10 25; 328(16):1624-1636.Walker MD, Shane E
  • CONCLUSIONS: Mild hypercalcemia is typically asymptomatic, while severe hypercalcemia is associated with nausea, vomiting, dehydration, confusion, somnolence, and coma. Asymptomatic hypercalcemia due to primary hyperparathyroidism is managed with parathyroidectomy or observation with monitoring, while severe hypercalcemia is typically treated with hydration and intravenous bisphosphonates.
  • Successful Management of Severe Hypercalcemia with Zoledronic Acid: A Report of Two Pediatric Cases. [Journal Article]
    J Clin Res Pediatr Endocrinol. 2022 Oct 20 [Online ahead of print]Kilci F, Jones JH, Çizmecioğlu-Jones FM
  • Severe hypercalcemia associated with vitamin D intoxication or malignancy in children is a rare and life-threatening condition. There is little published experience with Zoledronic acid in the treatment of pediatric severe hypercalcemia. Here, we present two pediatric cases of severe hypercalcemia, one due to vitamin D intoxication and the second to malignancy, in which Zoledronic acid was used a…
  • Novel Synergistic Combination of Pamidronate and Temozolomide for Breast Cancer Therapeutics. [Journal Article]
    Curr Cancer Drug Targets. 2022 Sep 21 [Online ahead of print]Syed N, Ilyas A, … Hashim Z
  • Objective Human breast cancer is among one of the major health concerns with high prevalence and mortality among women worldwide. Various cellular signaling pathways are implicated in carcinogenesis. One of the major pathways that affect the downstream cellular growth cascades is Mevalonate pathway (MVA). Inhibition of MVA is therapeutically beneficial for various cancers. Pamidronate (PAM) (MVA …
  • Vitamin D toxicity from an unusual and unexpected source: a report of 2 cases. [Case Reports]
    Horm Res Paediatr. 2022 Aug 26 [Online ahead of print]Silva C, Fung AWS, … Fox DA
  • CONCLUSIONS: We present 2 cases of hypervitaminosis D caused by a manufacturing error of a natural health product which did not claim to contain vitamin D. The use of dietary supplements is highly prevalent; their use should be incorporated in anamnesis and considered a potential source of toxicity when an alternative source cannot be found, regardless of the product label.
  • Clinical and therapeutic diversity in adult chronic nonbacterial osteomyelitis (CNO) of the sternocostoclavicular region: a meta-analysis. [Journal Article]
    Rheumatology (Oxford). 2023 Feb 01; 62(2):512-522.Leerling AT, Dekkers OM, … Winter EM
  • CONCLUSIONS: CNO/SCCH literature proves heterogeneous regarding diagnostics and treatment. Timely diagnosis is challenging and mainly follows from increased isotope uptake on nuclear examination. Biopsies, autoantibodies and HLA status are non-contributory, and biochemical inflammation only variably detected. Based on reported data, bisphosphonates and biologicals seem reasonably effective, but due to limitations in design and heterogeneity between studies the precise magnitude of their effect is uncertain. Fundamentally, international consensus seems imperative to advance clinical care for CNO/SCCH.
  • Medication-Related Osteonecrosis of the Jaws in the Pediatric Population. [Journal Article]
    J Oral Maxillofac Surg. 2022 10; 80(10):1686-1690.Neal TW, Schlieve T
  • CONCLUSIONS: While there were no reported cases of MRONJ in the present study, it is advisable to monitor pediatric patients who have received antiresorptive treatment closely. When possible, appropriate dental treatment should be completed prior to starting antiresorptive therapy. In the absence of reported MRONJ cases, dental extractions should not be withheld because of previous antiresorptive exposure and antiresorptive medication dosing need not be altered in the pediatric population.
New Search Next